ABBV - AbbVie Inc.
Close
180.14
-0.565 -0.314%
Share volume: 115,393
Last Updated: Mon 06 Jan 2025 08:30:01 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.79%
PREVIOUS CLOSE
CHG
CHG%
$180.70
-0.57
-0.31%
Fundamental analysis
54%
Profitability
50%
Dept financing
50%
Liquidity
12%
Performance
71%
Performance
5 Days
0.99%
1 Month
2.85%
3 Months
-6.40%
6 Months
8.83%
1 Year
12.26%
2 Year
8.81%
Key data
Stock price
$180.14
DAY RANGE
$179.32 - $181.94
52 WEEK RANGE
$156.35 - $207.32
52 WEEK CHANGE
$12.26
DIVIDEND
$1.55
EX-DIVIDEND DATE
07/15/2024
NEXT EARNINGS DATE
10/25/2024
Company detail
CEO: Richard A. Gonzalez
Region: US
Website: abbvie.com
Employees: 50,000
IPO year: -
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: abbvie.com
Employees: 50,000
IPO year: -
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism.
Recent news